• Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

United Therapeutics Corp

+ Add to Watchlist

UTH:GR

70.620 EUR 0.750 1.07%

As of 06:18:42 ET on 04/17/2014.

Snapshot for United Therapeutics Corp (UTH)

Open: 70.750 Day's Range: 70.620 - 70.810 Volume: 0
Previous Close: 69.870 52wk Range: 45.835 - 83.730 1-Yr Rtn: +55.60%

Stock Chart for UTH

No chart data available.
  • UTH:GR 70.730
  • 1D
  • 1M
  • 1Y
69.870
Interactive UTH Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for UTH

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) 8.6198
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2014) 11.3200
Est. PEG Ratio 0.6896
Market Cap (M EUR) 3,564.69
Shares Outstanding (M) 50.48
30 Day Average Volume 52
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 04/25/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for UTH

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for UTH

United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials.

Martine A RothblattChairman/CEO/FounderRoger A JeffsPresident/COO
John M FerrariCFO/TreasurerShola OyewoleChief Information Officer
More Company Profile & Key Executives for UTH

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil